Skip to main content

Table 5 Subsequent chemotherapy after nivolumab (n = 55)

From: Clinical features as potential prognostic factors in patients treated with nivolumab for highly pretreated metastatic gastric cancer: a multicenter retrospective study

Subsequent chemotherapy All patients (n = 55) Responder (n = 18) Non-responder (n = 37) p
 No 31 (56%) 6 (33%) 25 (68%) 0.022
 Yes 24 (44%) 12 (67%) 12 (32%)
Treatment after nivolumab All patients (n = 24) Responder (n = 12) Non-responder (n = 12) p
 Irinotecan 15 (62%) 6 (50%) 9 (75%) 0.226
 Taxane 9 (38%) 6 (50%) 3 (25%) 0.411
 Pyrimidine analog 7 (29%) 3 (25%) 4 (33%) 0.673
 Platinum 6 (25%) 3 (25%) 3 (25%) 1
 Ramucirumab 6 (25%) 4 (33%) 2 (17%) 0.645
 Trifluridine/tipiracil 2 (8%) 2 (17%) 0 (0%) 0.411